Deals In Depth: October 2012
In a deal valued at $272 million, AZ got exclusive global rights to Ardelyx’s NHE3 program. Pfizer exercised an option to buy spec pharma NextWave for $255 million up front. Biophama companies raised almost $2 billion in October propelled by public offerings. Early venture rounds dominated device financing, which totaled $193 million.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.